A COMPARATIVE EVALUATION OF PARACETAMOL, IBUPROFEN, AND COMBINATION THERAPY IN THE MANAGEMENT OF ACUTE MUSCULOSKELETAL PAIN: A PROSPECTIVE, OBSERVATIONAL STUDY

Authors

  • PRIYANKA KUMARI Department of Pharmacology, Nalanda Medical College, Patna, Bihar, India
  • SANTOSH KUMAR Department of Pharmacology, Nalanda Medical College, Patna, Bihar, India
  • ASHA SINGH Department of Pharmacology, Nalanda Medical College, Patna, Bihar, India

DOI:

https://doi.org/10.22159/ijcpr.2026v18i1.8044

Keywords:

Paracetamol, Ibuprofen, Combination therapy, Musculoskeletal pain, Analgesic efficacy, Numeric rating scale

Abstract

Objective: Acute musculoskeletal pain (AMP) is a common clinical condition that significantly impairs functional ability and quality of life. Paracetamol and ibuprofen are widely used analgesics, while combination therapy is believed to offer enhanced pain relief. This study aimed to compare the efficacy and safety of paracetamol, ibuprofen, and their combination in the management of acute musculoskeletal pain. To evaluate and compare analgesic efficacy and tolerability among paracetamol, ibuprofen, and combination therapy using the Numeric Rating Scale (NRS).

Methods: A prospective, objective, comparative study was conducted on 90 adult patients with acute musculoskeletal pain. Patients were randomly allocated into three groups (n=30 each): Group A (Paracetamol 1000 mg), Group B (Ibuprofen 400 mg), and Group C (Paracetamol 1000 mg+Ibuprofen 400 mg). Pain intensity was assessed using the NRS at baseline, 2 h, 4 h, and 6 h after administration. Adverse effects were recorded. Data were analyzed using ANOVA and chi-square tests.

Results: mean pain reduction at 6 h was highest in the combination group (5.8±1.2) compared to ibuprofen (4.6±1.5) and paracetamol (3.9±1.4), p<0.01. The onset of analgesia was faster with the combination therapy (within 1 hour). Adverse effects were mildand comparable across groups.

Conclusion: Combination therapy of paracetamol and ibuprofen provided superior pain relief with a faster onset and acceptable safety profile. It may be recommended for short-term management of acute musculoskeletal pain.

Downloads

Download data is not yet available.

References

1. Moore RA, Derry S, Straube S, Aldington DJ, Wiffen PJ Effects of paracetamol and ibuprofen combinations in acute pain. WHO global burden of disease study. Musculoskeletal disorders report. Pain. 2022. 2023 2;163(4):610-9.

3. Friedman BW, Irizarry E, Solorzano C. Randomized clinical trial of ibuprofen plus acetaminophen for acute pain. JAMA. 2023;329(2):145-54.

4. Parri N, Silvagni D, Chiarugi A, Cortis E, D Avino A, Lanari M. Paracetamol and ibuprofen combination for the management of acute mild-to-moderate pain in children: expert consensus using the nominal group technique (NGT). Ital J Pediatr. 2023 Mar 21;49(1):36. doi: 10.1186/s13052-023-01445-4, PMID 36945023, PMCID PMC10031994.

5. Derry CJ, Derry S, Moore RA. Single-dose oral ibuprofen and paracetamol for acute pain. Cochrane Database Syst Rev. 2023:CD010210. doi: 10.1002/14651858.CD010210.pub2.

6. Ong CK, Seymour RA, Lirk P, Merry AF. Combining paracetamol and ibuprofen in acute pain management. Br J Anaesth. 2024;132(3):460-9.

7. Hersh EV, Moore PA, Ross GL. Safety profile of ibuprofen and acetaminophen combination therapy. Clin Ther. 2022;44(8):1330-42.

8. Smith HS. Pain management: pharmacologic approaches. Pain Physician. 2022;25(1):S1-10.

9. Barden J, Edwards JE, McQuay HJ, Moore RA. Combination analgesics in acute pain. Pain. 2023;164(6):1120-8.

10. Lanas A, Chan FK. Peptic ulcer risk with NSAIDs and combination therapy. Gastroenterology. 2022;162(5):1454-68.

11. Derry S, Wiffen PJ, Kalso E. Oral non-opioid analgesics for acute pain: overview of Cochrane reviews. Cochrane Library; 2024:CD013544.

Published

15-01-2026

How to Cite

KUMARI, PRIYANKA, et al. “A COMPARATIVE EVALUATION OF PARACETAMOL, IBUPROFEN, AND COMBINATION THERAPY IN THE MANAGEMENT OF ACUTE MUSCULOSKELETAL PAIN: A PROSPECTIVE, OBSERVATIONAL STUDY”. International Journal of Current Pharmaceutical Research, vol. 18, no. 1, Jan. 2026, pp. 102-5, doi:10.22159/ijcpr.2026v18i1.8044.

Issue

Section

Original Article(s)